FDA Clearance Tracker · P160048-S022
Eversense® E3 Continuous Glucose Monitoring (CGM) System
Last checked: Nov 20, 2026Latest source record: Mar 30, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Mar 30, 2023
Approved
Time to decision
58 days
Received Jan 31, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P160048-S022
- Device name
- Eversense® E3 Continuous Glucose Monitoring (CGM) System
- Applicant
- Senseonics, Incorporated
- Applicant location
- Germantown, MD
- Received
- Jan 31, 2023
- Decided
- Mar 30, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P160048
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for modifying the Eversense E3 Transmitter, supporting mobile medical application, and the Instructions for Use for consistent use with the modified transmitter.
Source documents
Other decisions for Senseonics, Incorporated
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K241335 · Decided Sep 16, 2024 · 126 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.